zineryt 40 mg/ml +12 mg/ml powder and solvent for cuteanopus solution
astellas pharma d.o.o. - Еритромицин, комбинации - 40 mg/ml +12 mg/ml powder and solvent for cuteanopus solution
Надикса 1% крем - 25g
ferrer international s.a. -
dalacin t 10 mg/ml cutaneous solution
pfizer enterprises sarl - Клиндамицин - 10 mg/ml cutaneous solution
duac 10 mg/g + 30 mg/g gel
ГлаксоСмитКлайн ЕООД - 10 mg/g + 30 mg/g gel
erythran 1% ointment
Актавис ЕАД - Еритромицин - 1% ointment
davercin 25 mg/g gel
tarchomin pharmaceutical works polfa" s.a." - Еритромицин - 25 mg/g gel
acnex 10 mg/g + 0,25 mg/g gel
meda pharma gmbh & co. kg - 10 mg/g + 0,25 mg/g gel
acnerin, sol.cut.3% - 100ml
Унифарм - АД - Еритромицин -
tafinlar
novartis europharm limited - dabrafenib mesilate - Меланомът - Антинеопластични средства - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 и 5. Помощните терапия melanomadabrafenib в комбинация с trametinib е показан за адъювантного лечение на възрастни пациенти с iii състояние на меланом с Браф v600 мутация далеч, след пълна резекция на. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.
braftovi
pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - Антинеопластични средства - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.